These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 30381260)

  • 21. Are Therapies That Target α-Synuclein Effective at Halting Parkinson's Disease Progression? A Systematic Review.
    Rodger AT; ALNasser M; Carter WG
    Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
    Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transfer of human α-synuclein from the olfactory bulb to interconnected brain regions in mice.
    Rey NL; Petit GH; Bousset L; Melki R; Brundin P
    Acta Neuropathol; 2013 Oct; 126(4):555-73. PubMed ID: 23925565
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complexation of NAC-Derived Peptide Ligands with the C-Terminus of α-Synuclein Accelerates Its Aggregation.
    Jha NN; Ranganathan S; Kumar R; Mehra S; Panigrahi R; Navalkar A; Ghosh D; Kumar A; Padinhateeri R; Maji SK
    Biochemistry; 2018 Feb; 57(5):791-804. PubMed ID: 29286644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Generation of monoclonal antibodies against phosphorylated α-Synuclein at serine 129: Research tools for synucleinopathies.
    Fayyad M; Majbour NK; Vaikath NN; Erskine D; El-Tarawneh H; Sudhakaran IP; Abdesselem H; El-Agnaf OMA
    Neurosci Lett; 2020 Apr; 725():134899. PubMed ID: 32156613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alpha-Synuclein Fibrils Interact with Dopamine Reducing its Cytotoxicity on PC12 Cells.
    Khalife M; Morshedi D; Aliakbari F; Tayaranian Marvian A; Mohammad Beigi H; Azimzadeh Jamalkandi S; Pan-Montojo F
    Protein J; 2015 Aug; 34(4):291-303. PubMed ID: 26250981
    [TBL] [Abstract][Full Text] [Related]  

  • 27. α-Synuclein and nonhuman primate models of Parkinson's disease.
    Vermilyea SC; Emborg ME
    J Neurosci Methods; 2015 Nov; 255():38-51. PubMed ID: 26247888
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progress of immunotherapy of anti-α-synuclein in Parkinson's disease.
    Wang Z; Gao G; Duan C; Yang H
    Biomed Pharmacother; 2019 Jul; 115():108843. PubMed ID: 31055236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Naturally occurring autoantibodies against α-synuclein rescues memory and motor deficits and attenuates α-synuclein pathology in mouse model of Parkinson's disease.
    Huang YR; Xie XX; Ji M; Yu XL; Zhu J; Zhang LX; Liu XG; Wei C; Li G; Liu RT
    Neurobiol Dis; 2019 Apr; 124():202-217. PubMed ID: 30481547
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fibril growth and seeding capacity play key roles in α-synuclein-mediated apoptotic cell death.
    Mahul-Mellier AL; Vercruysse F; Maco B; Ait-Bouziad N; De Roo M; Muller D; Lashuel HA
    Cell Death Differ; 2015 Dec; 22(12):2107-22. PubMed ID: 26138444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration.
    Paumier KL; Luk KC; Manfredsson FP; Kanaan NM; Lipton JW; Collier TJ; Steece-Collier K; Kemp CJ; Celano S; Schulz E; Sandoval IM; Fleming S; Dirr E; Polinski NK; Trojanowski JQ; Lee VM; Sortwell CE
    Neurobiol Dis; 2015 Oct; 82():185-199. PubMed ID: 26093169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson's disease.
    Faustini G; Longhena F; Varanita T; Bubacco L; Pizzi M; Missale C; Benfenati F; Björklund A; Spano P; Bellucci A
    Acta Neuropathol; 2018 Oct; 136(4):621-639. PubMed ID: 30046897
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative Analysis of the Conformation, Aggregation, Interaction, and Fibril Morphologies of Human α-, β-, and γ-Synuclein Proteins.
    Jain MK; Singh P; Roy S; Bhat R
    Biochemistry; 2018 Jul; 57(26):3830-3848. PubMed ID: 29851342
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sensitive fluorescence polarization technique for rapid screening of alpha-synuclein oligomerization/fibrillization inhibitors.
    Luk KC; Hyde EG; Trojanowski JQ; Lee VM
    Biochemistry; 2007 Nov; 46(44):12522-9. PubMed ID: 17927212
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Review: Spreading the word: precise animal models and validated methods are vital when evaluating prion-like behaviour of alpha-synuclein.
    Rey NL; George S; Brundin P
    Neuropathol Appl Neurobiol; 2016 Feb; 42(1):51-76. PubMed ID: 26666838
    [TBL] [Abstract][Full Text] [Related]  

  • 36. α-synuclein aggregation and its modulation.
    Ghosh D; Mehra S; Sahay S; Singh PK; Maji SK
    Int J Biol Macromol; 2017 Jul; 100():37-54. PubMed ID: 27737778
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-human α-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-synuclein rat model of Parkinson's disease.
    Shahaduzzaman M; Nash K; Hudson C; Sharif M; Grimmig B; Lin X; Bai G; Liu H; Ugen KE; Cao C; Bickford PC
    PLoS One; 2015; 10(2):e0116841. PubMed ID: 25658425
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An Overview on the Role of α -Synuclein in Experimental Models of Parkinson's Disease from Pathogenesis to Therapeutics.
    Javed H; Kamal MA; Ojha S
    CNS Neurol Disord Drug Targets; 2016; 15(10):1240-1252. PubMed ID: 27658511
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intranasal administration of alpha-synuclein aggregates: a Parkinson's disease model with behavioral and neurochemical correlates.
    Gruden MA; Davydova TV; Narkevich VB; Fomina VG; Wang C; Kudrin VS; Morozova-Roche LA; Sewell RD
    Behav Brain Res; 2014 Apr; 263():158-68. PubMed ID: 24480422
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of Ser129 phosphorylation of α-synuclein in neurodegeneration of Parkinson's disease: a review of in vivo models.
    Sato H; Kato T; Arawaka S
    Rev Neurosci; 2013; 24(2):115-23. PubMed ID: 23314528
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.